###begin article-title 0
###xml 124 128 <span type="species:ncbi:10090">mice</span>
Targeted mutation of EphB1 receptor prevents development of neuropathic hyperalgesia and physical dependence on morphine in mice
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 598 606 598 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/+</italic>
###xml 680 688 680 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/-</italic>
###xml 718 726 718 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/-</italic>
###xml 976 984 974 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/+</italic>
###xml 994 1003 992 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 1007 1016 1005 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 1139 1148 1137 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 1152 1161 1150 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 1319 1328 1317 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 627 631 <span type="species:ncbi:10090">mice</span>
###xml 728 732 <span type="species:ncbi:10090">mice</span>
###xml 764 768 <span type="species:ncbi:10090">mice</span>
###xml 1016 1020 <span type="species:ncbi:10090">mice</span>
###xml 1161 1165 <span type="species:ncbi:10090">mice</span>
###xml 1199 1203 <span type="species:ncbi:10090">mice</span>
###xml 1328 1332 <span type="species:ncbi:10090">mice</span>
EphB receptor tyrosine kinases, which play important roles in synaptic connection and plasticity during development and in matured nervous system, have recently been implicated in processing of pain after nerve injury and morphine dependence. Subtypes of the EphB receptors that may contribute to the neuropathic pain and morphine dependence have not been identified. Here we demonstrate that the subtype EphB1 receptor is necessary for development of neuropathic pain and physical dependence on morphine. The results showed that peripheral nerve injury produced thermal hyperalgesia in wild-type (EphB1+/+) control littermate mice, but not in EphB1 receptor homozygous knockout (EphB1-/-) and heterozygous knockdown (EphB1+/-) mice. Hyperalgesia in the wild-type mice was inhibited by intrathecal administration of an EphB receptor blocking reagent EphB2-Fc (2 mug). Intrathecal administration of an EphB receptor activator ephrinB1-Fc (1 mug) evoked thermal hyperalgesia in EphB1+/+, but not EphB1-/- and EphB1+/- mice. Cellularly, nerve injury-induced hyperexcitability of the medium-sized dorsal root ganglion neurons was prevented in EphB1-/- and EphB1+/- mice. In chronically morphine-treated mice, most of the behavioral signs and the overall score of naloxone-precipitated withdrawal were largely diminished in EphB1-/- mice compared to those in the wild-type. These findings indicate that the EphB1 receptor is necessary for development of neuropathic pain and physical dependence on morphine and suggest that the EphB1 receptor is a potential target for preventing, minimizing, or reversing the development of neuropathic pain and opiate dependence.
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 401 402 401 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1009 1011 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1012 1014 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
There are striking similarities between neuropathic pain and opiate withdrawal-induced pain enhancement. Mechanisms of neuropathic pain and opiate dependence are complex and involve factors at the levels of receptors, ion channels, the cell and neural networks. Roles of diverse neurotransmitters, receptor systems and intracellular signaling proteins have been demonstrated in both neuropathic pain [1-12] and opiate dependence [13-24]. For instance, the system of glutamate/N-methyl-D-aspartate (NMDA) receptors/nitric oxide (NO) cascade is critically important to the development of neuropathic pain and morphine dependence and withdrawal [11,13,14,18,19,22-26]. However, the specific cellular and molecular mechanisms that control induction and maintenance of neuropathic pain and morphine dependence remain unclear. We have recently demonstrated a possibility that nerve injury or prolonged mu-opioid receptor (MOR) activation may elicit neuronal alterations that recapitulate events during development [27-29]. Certain molecules and the molecule-mediated activities that are important during development and "silent" in matured nervous system may become activated after nerve injury or prolonged MOR activation and therefore involve in development of neuropathic pain and opiate dependence.
###end p 4
###begin p 5
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 657 659 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 708 711 708 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 804 806 804 806 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 836 838 836 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 875 877 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 878 880 878 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1023 1025 1023 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1140 1142 1140 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1143 1145 1143 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1176 1178 1176 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1274 1276 1274 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1277 1279 1277 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1280 1282 1280 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1283 1285 1283 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1438 1440 1438 1440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1461 1462 1461 1462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1463 1465 1463 1465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1466 1468 1466 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1469 1471 1469 1471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1496 1498 1496 1498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1946 1954 1946 1954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/-</italic>
###xml 1984 1992 1984 1992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/-</italic>
###xml 1994 1998 <span type="species:ncbi:10090">mice</span>
Receptor tyrosine kinases (RTKs) play vital roles in transmitting external signals to the inside of many types of cells. Eph RTKs and ephrins are involved in tissue-border formation, cell migration, axon guidance, synapse formation and neural circuit assembly during development of the nervous system [30-33]. EphB receptors can also regulate development of glutamatergic synapses and their plasticity in adult nervous system by interaction with NMDA receptors [34-36]. The NMDA receptors have an established role in neural plasticity and are fundamental mediators of expression, development and maintenance of neuropathic pain and opiate dependence [21,37-40]. Activation of the NMDA receptors results in Ca2+ influx through the NMDA receptor ion-channel complex. The subsequent activation of various Ca2+-dependent enzymes, such as Ca2+/calmodulin-dependent kinase (CaMK) [41-43] and extracellular signal-regulated kinase (ERK) [44] play a critical role in induction of neuropathic pain and/or persistent opioid effects [40]. EphB receptors continue to be expressed (at lower levels) in the adult nervous system and, after neural injury [28,29] or prolonged MOR activation [27]. They are upregulated and redistributed in neurons, reactive astrocytes and oligodendrocytes [27-29,45-50]. Recent studies have shown that the EphB receptors can modulate sensory neuron excitability and spinal synaptic plasticity in acute inflammatory pain [51], neuropathic pain [9,28,29,52] and opiate dependence [27]. These studies demonstrate a critical role of the EphB receptors in the development of neuropathic pain and morphine dependence. Because of unavailability of the reagents and antibodies that could selectively activate and/or block a subtype of EphB receptor family, the specific EphB receptor that may play a key role in neuropathic pain and/or opiate dependence has not been identified. This study, using the EphB1 receptor homozygous knockout (EphB1-/-) and heterozygous knockdown (EphB1+/-) mice, provides the first evidence that the EphB1 receptor is required for development of neuropathic hyperalgesia and morphine dependence.
###end p 5
###begin title 6
Results
###end title 6
###begin title 7
###xml 66 70 <span type="species:ncbi:10090">mice</span>
EphB2-Fc inhibits nerve injury-induced thermal hyperalgesia in WT mice
###end title 7
###begin p 8
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 257 258 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 463 465 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 576 579 575 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 584 587 583 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 678 680 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 997 999 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 67 71 <span type="species:ncbi:10116">rats</span>
###xml 904 908 <span type="species:ncbi:10090">mice</span>
###xml 936 940 <span type="species:ncbi:10090">mice</span>
###xml 991 995 <span type="species:ncbi:10116">rats</span>
We began by confirming and extending our earlier demonstrations in rats that multiple intrathecal administration (i.t.) of EphB receptor blocking reagent EphB1-Fc or EphB2-Fc can inhibit production of CCI-induced thermal hyperalgesia [29]. As shown in Fig. 1, repetitive daily injection of EphB2-Fc (2 mug, i.t.) for 3 days, starting 30 min prior to injury, significantly inhibited CCI-induced thermal hyperalgesia for at least 14 days, the last tested day (Fig. 1A). The slight increase in thermal sensitivity of the foot contralateral to CCI treatment on the postoperative 5th and 7th day (groups of CCI + PBS and CCI + IgG-Fc) also disappeared after EphB2-Fc treatment (Fig. 1B). The EphB2-Fc treatment did not significantly affect thermal sensitivity in the sham-operated animals. Injections of PBS or IgG-Fc (2 mug, i.t.) did not significantly alter thermal sensitivity in the CCI and sham-operated mice. These results obtained in mice are similar to those we have recently reported in rats [29].
###end p 8
###begin p 9
###xml 0 83 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">An EphB receptor blocking reagent prevents thermal hyperalgesia after nerve injury.</bold>
###xml 197 201 <span type="species:ncbi:10090">mice</span>
###xml 537 541 <span type="species:ncbi:10090">mice</span>
An EphB receptor blocking reagent prevents thermal hyperalgesia after nerve injury. Repeated measurements are shown of thermal sensitivity of the foot withdrawal response in CCI- and sham-operated mice injected with EphB receptors blocking reagent EphB2-Fc (each 2 mug for continuous 3 days) and control vehicles PBS or IgG-Fc (2 mug). The arrow(s) indicates surgery (sham or CCI) or drug injection (i.t.) at the time point. Data represent changes of the withdrawals of the ipsilateral foot (A) and the contralateral (B). The numbers of mice in each group are shown in parentheses. **P < 0.01 indicate significant differences between sham group (Sham + PBS) and each of the other groups.
###end p 9
###begin title 10
###xml 103 107 <span type="species:ncbi:10090">mice</span>
Nerve injury-induced thermal hyperalgesia are prevented or largely diminished in EphB1-/- and EphB1+/- mice
###end title 10
###begin p 11
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 295 304 295 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 308 317 308 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 446 455 446 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 459 468 459 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 503 504 503 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 542 551 542 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 555 564 555 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 674 682 674 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/+</italic>
###xml 684 693 684 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 697 706 697 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 729 730 729 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 801 809 801 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/+</italic>
###xml 819 828 819 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 832 841 832 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 983 985 983 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1149 1151 1149 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 1275 1284 1275 1284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 1293 1302 1293 1302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 1318 1319 1318 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1606 1607 1606 1607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1707 1716 1707 1716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 1720 1729 1720 1729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 1794 1803 1794 1803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
###xml 468 472 <span type="species:ncbi:10090">mice</span>
###xml 575 579 <span type="species:ncbi:10090">mice</span>
###xml 706 710 <span type="species:ncbi:10090">mice</span>
###xml 841 845 <span type="species:ncbi:10090">mice</span>
###xml 1082 1086 <span type="species:ncbi:10090">mice</span>
###xml 1168 1172 <span type="species:ncbi:10090">mice</span>
###xml 1302 1306 <span type="species:ncbi:10090">mice</span>
###xml 1419 1423 <span type="species:ncbi:10090">mice</span>
###xml 1506 1510 <span type="species:ncbi:10090">mice</span>
###xml 1575 1579 <span type="species:ncbi:10090">mice</span>
###xml 1729 1733 <span type="species:ncbi:10090">mice</span>
###xml 1815 1819 <span type="species:ncbi:10090">mice</span>
Current available reagents, such as the ephrinB1-Fc, ephrinB2-Fc, EphB1-Fc and EphB2-Fc used in the present and previous studies [29,51], do not distinguish among different types of the ephrinBs and EphB receptors. Here we tested the role of the subtype EphB1 receptor in neuropathic pain using EphB1-/- and EphB1+/- mice. The results showed that CCI treatment induced thermal hyperalgesia in more than 90% of the WT, but in less than 10% of the EphB1-/- and EphB1+/- mice. Data are summarized in Table 1. Before receiving CCI treatment, the EphB1-/- and EphB1+/- and the WT mice exhibited similar thermal sensitivity. The time courses and changes of thermal sensitivity in EphB1+/+, EphB1+/- and EphB1-/- mice are shown in Fig. 2. The withdrawal latencies of the feet ipsilateral to CCI treatment in EphB1+/+, but not EphB1-/- and EphB1+/- mice were significantly decreased from the previous values each day after surgery, throughout the last test on the day 14 after surgery (Fig. 2A). Withdrawal latencies of the feet contralateral to CCI treatment in all of the three groups of mice were not significantly changed before and after surgery (Fig. 2B). Some of these mice were further used for electrophysiological recordings 8-14 days after nerve injury. In addition, 1/12 EphB1-/- and 1/11 EphB1+/- mice (see Table 1) showed thermal hyperalgesia after CCI treatment. The latencies of thermal withdrawal in these two mice decreased from preoperative values of 10-11 s to 7-8 s (~60%). Meanwhile, 1/12 WT mice that received CCI treatment showed no hyperalgesia. These three mice were not included in Fig. 2. We also observed the posture and gait and motor behavior related to the thermal test in those WT, EphB1-/- and EphB1+/- mice and did not find obvious differences between the WT and the EphB1-/- and EphB+/- mice.
###end p 11
###begin p 12
###xml 55 63 55 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/-</italic>
###xml 65 74 65 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 78 86 78 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB+/+ </italic>
###xml 0 91 0 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Nerve injury-induced changes of thermal sensitivity in <italic>EphB1-/-</italic>, <italic>EphB1+/- </italic>and <italic>EphB+/+ </italic>mice.</bold>
###xml 381 390 381 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 394 403 394 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/+ </italic>
###xml 417 426 417 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 430 438 430 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/+</italic>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 273 277 <span type="species:ncbi:10090">mice</span>
Nerve injury-induced changes of thermal sensitivity in EphB1-/-, EphB1+/- and EphB+/+ mice. The arrow indicates CCI treatment at the time point. Data represent changes of the hindpaw thermal withdrawals of the ipsilateral foot (A) and the contralateral (B). The numbers of mice in each group are shown in parentheses. **P < 0.01 indicates significant differences between groups of EphB1-/- and EphB1+/+ and groups of EphB1+/- and EphB1+/+.
###end p 12
###begin p 13
###xml 75 79 <span type="species:ncbi:10090">mice</span>
Thermal hyperalgesia in wide type and EphB1 receptor knockout or knockdown mice after nerve injury (CCI treatment) and intrathecal administration of ephrinB1-Fc.
###end p 13
###begin title 14
###xml 83 87 <span type="species:ncbi:10090">mice</span>
EphrinB1-Fc evokes thermal hyperalgesia in EphB1+/+, but not EphB1-/- and EphB1+/- mice
###end title 14
###begin p 15
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 521 523 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 602 604 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 605 607 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 113 117 <span type="species:ncbi:10116">rats</span>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
###xml 570 574 <span type="species:ncbi:10116">rats</span>
EphrinB1-Fc can activate EphB receptors and evoke thermal hyperalgesia via interaction with the NMDA receptor in rats [29,51]. The results here showed that a single injection of ephrinB1-Fc (1 mug, i.t.) caused a rapid onset (within 2 h) and prolonged (at least 24 h) thermal hypersensitivity in mice. EphrinB1-Fc-induced thermal hypersensitivity was prevented by a prior injection of an NMDA receptor antagonist, MK-801 (5 mug). IgG-Fc (2 mug, i.t.) did not produce thermal hypersensitivity. Data are summarized in Fig. 3A. These results in mice are similar to that in rats we have recently reported [29,51].
###end p 15
###begin p 16
###xml 54 62 54 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/-</italic>
###xml 64 73 64 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 77 85 77 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB+/+ </italic>
###xml 0 90 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">EphrinB1-Fc-induced changes of thermal sensitivity in <italic>EphB1-/-</italic>, <italic>EphB1+/- </italic>and <italic>EphB+/+ </italic>mice.</bold>
###xml 397 405 393 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/+</italic>
###xml 418 427 414 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 431 440 427 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 440 444 <span type="species:ncbi:10090">mice</span>
###xml 524 528 <span type="species:ncbi:10090">mice</span>
EphrinB1-Fc-induced changes of thermal sensitivity in EphB1-/-, EphB1+/- and EphB+/+ mice. A: EphrinB1-Fc (1 mug)-induced thermal hypersensitivity in WT mice is prevented by NMDA receptor antagonist MK-801 (5 mug, pretreated). Injection of IgG-Fc (1 mug) did not change the thermal sensitivity, nor did MK-801 alone affect the responses. B: EphrinB1-Fc (1 mug) induced thermal hypersensitivity in EphB1+/+, but not in EphB1+/- and EphB1-/- mice. The values of thermal withdrawal are mean values of both feet. The numbers of mice in each group are shown in parentheses. The arrow indicates drug injection (i.t.) at the time point. **P < 0.01 indicate significant differences between groups of the different treatments and the PBS control.
###end p 16
###begin p 17
###xml 41 50 41 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 54 63 54 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 255 264 254 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/+ </italic>
###xml 304 313 303 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 334 343 333 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 355 356 354 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 414 422 413 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/+</italic>
###xml 424 433 423 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 437 446 436 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 469 471 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 503 512 502 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 624 625 623 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 63 67 <span type="species:ncbi:10090">mice</span>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 446 450 <span type="species:ncbi:10090">mice</span>
###xml 512 516 <span type="species:ncbi:10090">mice</span>
Additional experiments were performed in EphB1+/- and EphB1-/- mice to test if the EphB1 receptor is required for the ephrinB1-Fc-induced thermal hyperalgesia. The results showed that ephrinB1-Fc (1 mug, i.t.) produced thermal hyperalgesia in 100% of the EphB1+/+ mice tested, while in only 16.7% of the EphB1+/- and none (0%) of the EphB1-/- mice (Table 1). The time courses and changes of thermal sensitivity in EphB1+/+, EphB1+/- and EphB1-/- mice are shown in Fig. 3B. Data from the 16.7% (2/12) of EphB1+/- mice that exhibited moderate thermal hypersensitivity following ephrinB1-Fc injection were not included in Fig. 3.
###end p 17
###begin title 18
###xml 111 115 <span type="species:ncbi:10090">mice</span>
Nerve injury-induced DRG neuron hyperexcitability are prevented or largely diminished in EphB1-/- and EphB1+/- mice
###end title 18
###begin p 19
###xml 437 438 437 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 550 559 550 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 563 572 563 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 572 576 <span type="species:ncbi:10090">mice</span>
Hyperexcitability of DRG neurons following nerve injury contributes to sensitization of the central nociceptive neurons in dorsal horn (DH) of the spinal cord, leading to chronic pain and hyperalgesia. Hyperexcitability of DRG neurons after CCI and other forms of injury is often manifested as depolarization of resting membrane potential (RMP), a decrease in action potential (AP) current threshold, and increased repetitive discharge [5,11,25,29,53-58]. We examined these three electrophysiological properties of the intact DRG neurons from WT and EphB1-/- and EphB1+/- mice to test the possibility that the EphB1 receptor contributes to DRG neuron hyperexcitability.
###end p 19
###begin p 20
###xml 111 113 106 108 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 121 123 116 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 136 168 131 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/+, EphB1+/- and EphB1-/- </italic>
###xml 246 247 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 590 612 585 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- and EphB1-/- </italic>
###xml 665 666 660 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 168 172 <span type="species:ncbi:10090">mice</span>
###xml 366 370 <span type="species:ncbi:10090">mice</span>
###xml 612 616 <span type="species:ncbi:10090">mice</span>
###xml 819 823 <span type="species:ncbi:10090">mice</span>
A total of 235 medium-sized neurons [diameter (mean +/- SE): 39.6 +/- 0.43 mum] were recorded from the intact L4 and/or L5 DRG from the EphB1+/+, EphB1+/- and EphB1-/- mice that previously received sham or CCI treatment (from those shown in Fig. 2), respectively. The results showed that CCI treatment significantly increased excitability of the neurons from the WT mice, the RMP was depolarized, the AP current threshold lowered, the repetitive discharge following depolarizing current increased. However, CCI treatment did not significantly alter these properties of the DRG neurons from EphB1+/- and EphB1-/- mice. Examples are given and data summarized in Fig. 4. These results indicate that a proper level of EphB1 receptor is required for the development of hyperexcitability of DRG neurons after nerve injury in mice.
###end p 20
###begin p 21
###xml 60 68 60 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/-</italic>
###xml 70 79 70 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 83 91 83 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB+/+ </italic>
###xml 0 96 0 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Alteration of excitability of medium-sized DRG neurons from <italic>EphB1-/-</italic>, <italic>EphB1+/- </italic>and <italic>EphB+/+ </italic>mice.</bold>
###xml 668 676 668 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/+</italic>
###xml 765 773 765 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/+</italic>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
Alteration of excitability of medium-sized DRG neurons from EphB1-/-, EphB1+/- and EphB+/+ mice. A, Examples of neural responses recorded intracellularly during the test sequence used to determine AP threshold. Only one of the depolarizing 50-ms pulses (bottom) and corresponding responses (top) are illustrated in each case. B, Examples of neural discharge patterns evoked by depolarizing current. Alterations of the RMP, AP threshold current and repetitive discharge are summarized in C, D and E, respectively. The numbers of cells tested in each group are shown in parentheses. *P < 0.05, **P < 0.01 indicate significant differences compared with the group of sham EphB1+/+. ##P < 0.01 indicate the significant differences compared with the group of CCI-treated EphB1+/+.
###end p 21
###begin title 22
###xml 97 101 <span type="species:ncbi:10090">mice</span>
Behavioral signs of naloxone-precipitated morphine withdrawal are largely diminished in EphB1-/- mice
###end title 22
###begin p 23
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 370 379 370 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 443 452 443 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5I</xref>
###xml 594 603 594 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5J</xref>
###xml 311 314 <span type="species:ncbi:9615">dog</span>
###xml 379 383 <span type="species:ncbi:10090">mice</span>
###xml 408 412 <span type="species:ncbi:10090">mice</span>
###xml 452 456 <span type="species:ncbi:10090">mice</span>
###xml 491 495 <span type="species:ncbi:10090">mice</span>
###xml 603 607 <span type="species:ncbi:10090">mice</span>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
Naloxone-precipitated morphine withdrawal results in a characteristic morbidity, including anxiety, nausea, insomnia, hot and cold flashes, muscle aches, perspiration, diarrhea, etc. As shown in Figure 5, most of the observed behavioral signs, the backward walking, chewing, diarrhea, jump, ptosis, tremor, wet dog shake and weight loss were significantly alleviated in EphB1-/- mice compared to those in WT mice except that the paw tremor in EphB1-/- mice was not different from that in WT mice (Fig. 5I). Consistent with these changes, the overall withdrawal score significantly decreased in EphB1-/- mice compared to that in WT mice (Fig. 5J). These results suggest that the EphB1 receptor may be required for development of morphine dependence.
###end p 23
###begin p 24
###xml 0 75 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">EphB1 receptor knockout attenuates behavioral signs of morphine withdrawal.</bold>
###xml 146 155 146 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/+ </italic>
###xml 175 184 175 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 201 205 <span type="species:ncbi:10090">mice</span>
###xml 213 217 <span type="species:ncbi:10090">mice</span>
###xml 398 402 <span type="species:ncbi:10090">mice</span>
###xml 828 831 <span type="species:ncbi:9615">dog</span>
###xml 884 888 <span type="species:ncbi:10090">mice</span>
###xml 944 948 <span type="species:ncbi:10090">mice</span>
###xml 1014 1018 <span type="species:ncbi:10090">mice</span>
EphB1 receptor knockout attenuates behavioral signs of morphine withdrawal. A-I: Behavioral signs of naloxone-precipitated morphine withdrawal in EphB1+/+ (wild-type, WT) and EphB1-/- (EphB1 knockout) mice. Those mice were injected (i.p.) with repeated pulses of morphine given in 7 escalating doses every 8 h (20, 40, 60, 80, 100, 100, and 100 mg/kg). Two hours after the last morphine injection, mice were injected with naloxone (1 mg/kg, s.c.), and withdrawal symptoms were monitored for 30 min after naloxone administration. J: Overall withdrawal score. In addition to measuring individual withdrawal signs (A-I), an overall opiate withdrawal score was calculated as (no. of backward walking steps x 0.1) + (diarrhea x 2) + (no. of jumps x 0.1) + (paw tremor x 0.1) + (ptosis) + (tremor) + (% weight loss x 5) + (no. of wet-dog shakes) as described in the Methods. The numbers of mice in each group are shown in parentheses in A-J (the ten mice in each group of EphB1+/+ and EphB1-/- through A-J were the same mice). **, p < 0.01, indicate significant differences compared with the WT control group.
###end p 24
###begin title 25
Discussion
###end title 25
###begin p 26
###xml 248 257 248 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 261 270 261 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 531 540 531 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 544 553 544 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 718 727 718 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 270 274 <span type="species:ncbi:10090">mice</span>
###xml 326 330 <span type="species:ncbi:10090">mice</span>
###xml 553 557 <span type="species:ncbi:10090">mice</span>
###xml 727 731 <span type="species:ncbi:10090">mice</span>
###xml 756 760 <span type="species:ncbi:10090">mice</span>
This study investigated roles of subtype EphB1 of EphB receptors in development of neuropathic pain and morphine dependence. The major findings are 1) peripheral nerve injury (CCI treatment) produces significant thermal hyperalgesia in WT, but not EphB1-/- and EphB1+/- mice. Meanwhile, CCI-induced thermal hyperalgesia in WT mice is inhibited by spinal administration of a reagent that can block the EphB receptors; 2) spinal administration of a reagent that can activate EphB receptors evokes thermal hyperalgesia in WT, but not EphB1-/- and EphB1+/- mice; 3) EphB1 receptor knockout or down prevents CCI-induced DRG neuron hyperexcitability; and 4) behavioral signs of morphine withdrawal are greatly suppressed in EphB1-/- mice compared to those in WT mice. These findings provide the first evidence that the subtype EphB1 receptor is necessary for development of thermal hyperalgesia and the associated sensory neuron hyperexcitability after nerve injury and pain enhancement following morphine withdrawal.
###end p 26
###begin title 27
EphB1 receptor is necessary for development of neuropathic hyperalgesia and morphine dependence
###end title 27
###begin p 28
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 1110 1118 1110 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/-</italic>
###xml 1130 1138 1130 1138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/-</italic>
###xml 1511 1519 1511 1519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/+</italic>
###xml 647 652 <span type="species:ncbi:9606">human</span>
###xml 1140 1144 <span type="species:ncbi:10090">mice</span>
###xml 1649 1653 <span type="species:ncbi:10090">mice</span>
Recent studies have indicated that EphB receptors, which play an important role in synaptic connection and plasticity during development and in matured nervous system, are involved in pain processing [28,29,51,52] and opiate dependence [27]. We have recently shown that ephrinBs and EphB receptor proteins are upregulated and redistributed in DRG and DH after nerve injury [28,29], EphB receptor proteins upregulated in DH after chronic morphine treatment [27], and activation of EphB receptors is required for the development of neuropathic pain [28,29] and morphine dependence [27]. The Eph-receptors constitute the largest subfamily of RTKs in human genome, with 13 members divided into an A-subclass (EphA1-EphA8) and a B-subclass (EphB1-EphB4, EphB6) [59,60]. Although the importance of EphB receptors in neuropathic pain and morphine dependence has been demonstrated, the specific subtypes of EphB receptors have not been identified because of the unavailability of reagents and antibodies that could selectively activate and/or block an EphB receptor subtype. This study, using EphB1 receptor knockout (EphB1-/-) and down (EphB1+/-) mice, demonstrates, for the first time, that the subtype EphB1 receptor is required for the development of neuropathic hyperalgesia and morphine dependence. In addition, our results show that knockdown of the EphB1 receptor produces similar effect on thermal sensitivity as knockout. This result further suggests that a proper expression levels of the WT EphB1 receptor (EphB1+/+) is necessary for development of neuropathic hyperalgesia, and that reduction to approximately 50% normal levels in heterozygous mice sufficient to prevent this form occurring.
###end p 28
###begin title 29
The forward signaling of EphB1 receptor is involved in development of neuropathic hyperalgesia and morphine dependence
###end title 29
###begin p 30
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 666 667 666 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 668 669 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 670 671 670 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 683 686 683 686 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 827 829 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 871 873 871 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 904 906 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 907 909 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 983 985 983 985 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1142 1144 1142 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1525 1529 <span type="species:ncbi:10090">mice</span>
The ephrinB-EphB interaction is well known to lead bidirectional signals which are propagated into the ephrinB-expressing cells (reverse signaling) and the EphB-expressing cells (forward signaling). Depending upon context, both forward signaling and reverse signaling play important roles, either pre- or postsynaptically, in synaptic plasticity. Upregulation and redistribution of the EphB receptors in the DH after nerve injury [28,29] or prolonged MOR activation [27] may initiate a cascade of postsynaptic effects, starting with EphB receptor activation, then intracellular signaling through Src-family kinases[51,61], and resulting in NMDA receptor activation [1-4,6-12] with Ca2+ influx through the NMDA receptor ion-channel complex. The NR2B subunit of NMDA receptor activation may be important for morphine dependence [27]. The subsequent activation of various Ca2+-dependent signaling pathways [38,62] plays a central role in neuropathic pain and morphine dependence. The Ca2+/CaMKII protein can phosphorylate (activate) cyclic AMP related element binding (CREB), which leads to increases in c-Fos mRNA and c-Fos protein expression [63]. Gene expression is thought to play an important role in many forms of plasticity, including hyperalgesia and morphine dependence. The present study further shows that binding to the EphB1 receptor is required for ephrinBs such as ephrinB1-Fc, which may also bind to EphB1-4 and EphA4 receptors, to promote behavioral hyperalgesia and that the EphB1 receptor protein-null mutant mice fail to development hyperalgesia or morphine dependence. These findings support a role of the EphB1 receptor forward signaling in neuropathic hyperalgesia and opiate dependence.
###end p 30
###begin p 31
###xml 56 65 56 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 69 78 69 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 410 419 410 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/- </italic>
###xml 423 432 423 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
###xml 432 436 <span type="species:ncbi:10090">mice</span>
In addition, we have noticed that a small proportion of EphB1-/- and EphB1+/- mice (~10%) exhibit hyperalgesia after nerve injury or spinal administration of ephrinB1-Fc (see Table 1). Possible reasons may include that some pain related signals, the neurotransmitters, neuromodulators, receptors, ion channels and intracellular pathways that we have not examined, might have been modified or integrated in the EphB1-/- and EphB1+/- mice.
###end p 31
###begin title 32
Roles of the reverse signaling of EphB1 receptor in development of neuropathic hyperalgesia and morphine dependence
###end title 32
###begin p 33
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 915 917 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1327 1329 1327 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1380 1382 1380 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1383 1385 1383 1385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1397 1399 1397 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1400 1402 1400 1402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 1403 1405 1403 1405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 1424 1426 1424 1426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1427 1429 1427 1429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 503 507 <span type="species:ncbi:10090">mice</span>
###xml 689 693 <span type="species:ncbi:10090">mice</span>
###xml 1046 1050 <span type="species:ncbi:10090">mice</span>
EphB stimulation of reverse signaling through activation of ephrinBs may also be involved in the development of neuropathic hyperalgesia after nerve injury. Upregulation and redistribution of ephrinBs in DRG and DH [28,29] may be initiated/regulated by the nerve injury, but probably also caused by increased reverse signaling mediated by EphB receptors in DRG and/or DH where EphB receptor proteins are upregulated after nerve injury [28,29]. If so, loss of postsynaptic EphB1 receptor in the EphB1-/- mice may result in loss of reverse signaling and therefore the subsequent activities. In contrast, chronic morphine treatment causes significant upregulation of EphB receptor protein in mice spinal cord, while expression of ephrinBs (ephrinB1, ephrinB2, and PY99) remains unchanged [27]. The behavioral and neurochemical signs of morphine dependence are largely diminished by the EphB receptor blocking reagent [27]. The present study further shows that the behavioral signs of morphine withdrawal are prevented in EphB1 receptor protein-null mice. Taken together, these findings suggest that reverse signaling may participate in development of neuropathic hyperalgesia, but seems to be less important in development of morphine dependence. The EphB1 receptor may act by interaction with the NR2B subtype of NMDA receptors [27] and then activate the postsynaptic signals ERKs [27,64] and CREB [27,65,66], or NO pathways [46,67], while the ephrinBs do not seem to be necessary in this process. However, at this point in our analysis there is no direct evidence that allows us to definitively rule in or out a role for reverse signaling in neuropathic hyperalgesia and morphine dependence.
###end p 33
###begin title 34
EphB1 receptor is necessary for development of sensory neuron hyperexcitability after nerve injury
###end title 34
###begin p 35
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1314 1316 1314 1316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1317 1319 1317 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 1320 1322 1320 1322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 980 984 <span type="species:ncbi:10090">mice</span>
###xml 1669 1673 <span type="species:ncbi:10090">mice</span>
Hyperexcitability of DRG neurons following nerve injury contributes to the sensitization of central nociceptive neurons in DH, leading to chronic pain and hyperalgesia. The findings that reagents that can activate the EphB receptors increase excitability and the reagents that can block the EphB receptors suppress hyperexcitability of the nerve-injured DRG neurons [29] suggest widespread effects of these receptors on the excitability of presynaptic primary sensory neurons and represent the first demonstration that ephrinB-EphB receptor signaling can regulate excitability in any neurons. This study provides further evidence that the EphB1 receptor knockout or down can prevent the DRG neurons from being hyper-excitable following nerve injury, suggesting that the EphB1 receptor is required for the development of DRG neuron hyperexcitability. These findings also indicate a sensory neuron mechanism underlying the behavioral analgesia in EphB1 receptor protein-null mutant mice. It remains unknown how the EphB receptors, which are upregulated in DRG and DH after nerve injury, regulate the DRG neuron excitability. One possibility is that activation of the EphB1 receptor may modulate the sodium channel Nav1.7 via regulation of the small G-protein Ras-ERK-mitogen activated protein kinase (MAPK) pathway [29,68-74]. The EphB receptors on DRG neurons would be activated directly by certain initial injury signals from peripheral and/or by the upregulated ephrinBs, by the reverse signaling of EphB receptors from DH through activation of ephrinBs, and probably by other retrograde signaling through ephrinBs. The signaling would be lost in the knockout or down mice DRG due to loss of the postsynaptic EphB1. There is lack of evidence supporting or excluding these possibilities.
###end p 35
###begin title 36
EphB1 receptor is a potential therapeutic target for neuropathic hyperalgesia and morphine dependence
###end title 36
###begin p 37
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 843 851 843 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/-</italic>
###xml 874 882 874 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/-</italic>
###xml 161 169 <span type="species:ncbi:9606">patients</span>
Both neuropathic pain and opiate dependence continue to pose major challenges. Current drugs and nondrug therapies offer very limited substantial pain relief to patients. The present and several recent studies have provided evidence that the neuropathic hyperalgesia and morphine dependence can be markedly suppressed by knockout/down of EphB1 receptor and/or spinal administration of an EphB receptor blocking reagent or ephrinB2 siRNA [27-29,51,52]. These findings, in addition to supporting a novel mechanism contributing to neuropathic pain and opiate dependence and a novel role for EphB receptor signaling in development of neuropathic pain and morphine dependence, open up a new avenue to preventing, minimizing, or reversing the development of neuropathic pain and morphine dependence. The similar analgesic effect of EphB1 knockdown (EphB1+/-) to that of knockout (EphB1-/-) suggests a further implication in development of new analgesics.
###end p 37
###begin title 38
Conclusion
###end title 38
###begin p 39
We here provide the first evidence that the subtype EphB1 of EphB receptors is necessary for the development of neuropathic pain and morphine dependence. We hypothesize that nerve injury and prolonged MOR activation can elicit neuronal alterations that may result in activation of certain molecules, such as the ephrinB-EphB receptor signaling, that are important in synaptic connection and plasticity during development and "silent" in matured nervous system. These molecules therefore become critical to the development of neuropathic pain or morphine dependence. The activated molecules may be the therapeutic targets for preventing, minimizing and/or treating neuropathic pain and physical dependence on opiate.
###end p 39
###begin title 40
Methods
###end title 40
###begin title 41
Animals
###end title 41
###begin p 42
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 119 128 119 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/- </italic>
###xml 235 243 235 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1-/-</italic>
###xml 270 278 270 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/-</italic>
###xml 301 309 301 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EphB1+/+</italic>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 536 537 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 336 340 <span type="species:ncbi:10090">mice</span>
###xml 411 415 <span type="species:ncbi:10090">mice</span>
###xml 509 513 <span type="species:ncbi:10090">mice</span>
The generation of EphB1 receptor protein-null mutant mice has been previously described [75,76]. For the present study EphB1+/- heterozygous males and females in the CD-1 background were bred to obtain a cohort of homozygous knockout (EphB1-/-), heterozygous knockdown (EphB1+/-), and wild-type (WT) (EphB1+/+) control littermate adult mice (25-30 g-wt). All breeding was done by the Henkemeyer group and adult mice were provided to the Song group, who were blinded to the genotypes. Additional WT, male CD-1 mice (25-30 g-wt) (Fig. 1, 2) were obtained from Charles River Laboratories, MA, USA. All experimental procedures were conducted in accordance with the regulations of the ethics committee of the International Association for the Study of Pain and approved by Parker Research Institute Animal Care and Use Committee.
###end p 42
###begin title 43
Neuropathic pain model and assessment of thermal hyperalgesia
###end title 43
###begin p 44
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 152 156 <span type="species:ncbi:10116">rats</span>
###xml 211 216 <span type="species:ncbi:10090">mouse</span>
Neuropathic pain was produced by peripheral nerve injury mimicked by modification of model of chronic construction injury of the sciatic nerve (CCI) in rats [77]. In brief, the left common sciatic nerve of each mouse was exposed at the mid-thigh level. Proximal to the sciatic nerve's trifurcation, approximately 4 mm of nerve was freed of adhering tissue and three ligatures (6-0 chromic gut) were tied loosely around it with about 0.5 mm between ligatures. All surgeries were done under anesthesia induced by intraperitoneal injection (i.p.) of sodium pentobarbital (50 mg/kg). After surgery, the muscle and skin layers were sutured.
###end p 44
###begin p 45
###xml 277 278 277 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1184 1185 1184 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1187 1188 1187 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1311 1312 1311 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 289 294 <span type="species:ncbi:10090">mouse</span>
###xml 809 813 <span type="species:ncbi:10090">mice</span>
###xml 1003 1007 <span type="species:ncbi:10090">mice</span>
###xml 1588 1592 <span type="species:ncbi:10090">mice</span>
Thermal hyperalgesia was indicated by a decrease in the latency of foot withdrawal evoked by a radiant heat generated and controlled by a IITC Model 336 Analgesia Meter (Life Science, Series 8, Woodland Hill, CA). The protocol was similar to that we have described previously [5,11]. Each mouse was placed in a box (10 x 12 x 12 cm) containing a smooth, temperature-controlled glass floor. The heat source was focused on a portion of the hindpaw, which was flush against the glass, and a radiant thermal stimulus was delivered to that site. The stimulus shut off automatically when the hindpaw moved (or after 20 sec to prevent tissue damage). The intensity of the heat stimulus was maintained constant throughout all experiments. The elicited paw movement occurred at latency between 9 and 15 sec in control mice. Thermal stimuli were delivered 3 times to each hind paw at 5-10 min intervals. The change in latency of foot withdrawal to the heat stimulus was used to judge the thermal sensitivity. The mice were tested on each of two successive days prior to surgery. The withdrawal latencies of the feet ipsilateral and contralateral to nerve injury were expressed separately (Fig. 1, 2). For the results expressing i.t. ephrinB1-Fc-induced thermal hyperalgesia, the values are mean values of both feet (Fig. 3). To examine effects of multiple administrations of the drugs on CCI-induced thermal hyperalgesia, the postoperative tests were conducted 3, 5, 7 and on the day of electrophysiological recording (days 9-14). To test the effects of ephrinB1-Fc on the thermal sensitivity, the mice were tested on each of 2 successful hours prior to injection and the postinjective tests were conducted 2, 4, 8, 12 and 24 h after injection.
###end p 45
###begin title 46
Opiate Withdrawal
###end title 46
###begin p 47
###xml 624 626 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 208 212 <span type="species:ncbi:10090">mice</span>
###xml 611 614 <span type="species:ncbi:9615">dog</span>
Mice were injected (i.p.) with repeated pulses of morphine (Sigma, St. Louis, MO) given in 7 escalating doses every 8 h (20, 40, 60, 80, 100, 100, and 100 mg/kg). Two hours after the last morphine injection, mice were injected with naloxone (Sigma) (1 mg/kg, s.c.), and withdrawal symptoms were monitored for 30 min after naloxone administration. In addition to measuring individual withdrawal signs, an overall opiate withdrawal score was calculated as (no. of backward walking steps x 0.1) + (diarrhea x 2) + (no. of jumps x 0.1) + (paw tremor x 0.1) + (ptosis) + (tremor) + (% weight loss x 5) + (no. of wet-dog shakes) [20].
###end p 47
###begin title 48
Excised, intact ganglion preparation
###end title 48
###begin p 49
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 46 48 46 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 56 58 56 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 408 409 408 409 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 411 412 411 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 422 423 422 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 446 447 446 447 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 461 463 461 463 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 134 138 <span type="species:ncbi:10090">mice</span>
###xml 198 202 <span type="species:ncbi:10116">rats</span>
###xml 584 589 <span type="species:ncbi:10090">mouse</span>
In vitro preparations of DRGs were made from L4 and/or L5 ganglia for electrophysiological studies from the WT, EphB1-/- and EphB1+/- mice. The procedure was similar to that described previously in rats [5,11]. Briefly, a laminectomy was performed under anesthesia after the last behavioral tests. Ice-cold, oxygenated, artificial cerebrospinal fluid (ACSF), consisting of (in mM) 130 NaCl, 3.5 KCl, 1.25 NaH2PO4, 24 NaHCO3, 10 dextrose, 1.2 MgCl2, and 1.2 CaCl2 (pH = 7.3) was dripped onto the surface of the ganglion during the surgical procedure. The ganglion was removed from the mouse and placed in a 35-mm petri dish filled with the ACSF. Under a dissecting microscope, the perineurium and epineurium were peeled away from the ganglion and the attached sciatic nerve and dorsal roots transected adjacent to the ganglion. The ganglion was then placed in the recording chamber and mounted on the stage of an upright microscope (BX50-WI, Olympus, Japan). A U-shaped stainless steel rod with 4 pieces of silver wire crossing from one side to the other was used to hold the ganglion gently in place. The DRG was incubated in the oxygenated ACSF at room temperature (21-22degreesC).
###end p 49
###begin title 50
Electrophysiological recordings
###end title 50
###begin p 51
###xml 713 714 712 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 715 717 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
Intracellular recordings were made from the intact DRG somata 2-6 h after dissociation using conventional bridge-balance techniques (Axoclamp-2B, Axon Instruments, Foster City, CA) and analyzed with PCLAMP-8 under Windows 98 (Axon Instruments). Somata of the DRG neurons were classified visually by their diameters. Only the medium-sized (soma diameter 30-50 mum) DRG neurons were included in this study. Glass microelectrodes were fabricated with a Flaming/Brown micropipette puller (Model P-97/PC, Sutter Instruments.) and filled with 2 M potassium acetate (pH = 7.2). The protocols used to record and measure electrophysiological properties of the DRG neurons were similar to those we have described recently [5,11]. Resting membrane potential (RMP) was taken 2-3 min after RMP had stabilized. All neurons accepted for testing exhibited a stable RMP of -40 mV or more negative. Action potential (AP) current threshold was examined by delivering depolarizing currents of 0.05-4 nA (50 ms duration) in increments of 0.1-0.2 nA until an AP was evoked. Repetitive discharge of each neuron was measured by counting the spikes evoked by intracellular injection of standardized depolarizing currents at 2.5 x threshold strength (x1000 ms).
###end p 51
###begin title 52
Drug administration
###end title 52
###begin p 53
###xml 260 265 <span type="species:ncbi:9606">human</span>
###xml 389 394 <span type="species:ncbi:10090">mouse</span>
###xml 531 536 <span type="species:ncbi:10090">mouse</span>
For the experiments on CCI-induced hyperalgesia, the following vehicle and drugs were administrated intrathecally (i.t., all in 5 mul) by means of lumbar puncture under brief inhalational anesthesia: PBS, ephrinB1-Fc chimera (1 mug), EphB2-Fc chimera (2 mug), human IgG-Fc fragment (IgG-Fc, 2 mug) and MK-801 (5 mug). The PBS was used as vehicle control. The molecule ephrinB1-Fc chimera (mouse recombinant; E 0778, Sigma) was used as an EphB receptor activator and it can bind to EphB1-4 and EphA4. The molecule EphB2-Fc chimera (mouse recombinant; Sigma, E9402) was used as an EphB receptors blocking reagent and it can bind to ephrinB1-3. The IgG-Fc was used as Fc control (Jackson Laboratory, Bar Harbor, ME). MK-801 was used as an NMDA receptor antag onist.
###end p 53
###begin title 54
Statistical tests
###end title 54
###begin p 55
###xml 430 434 <span type="species:ncbi:10090">mice</span>
###xml 610 614 <span type="species:ncbi:10090">mice</span>
SPSS Rel 15 (SPSS Inc., Chicago, IL) was used to conduct all the statistical analyses. Changes in withdrawal latencies over time were tested with two-way ANOVA with repeated measures followed by Bonferroni post hoc tests. One-way ANOVA followed by Bonferroni post hoc tests was used to test the hypothesis that RMP, excitability (including the AP current threshold and number of APs evoked by 1 s pulse) in CCI groups of EphB1+/+ mice were different from those of EphB1-/- and +/- and the sham WT groups. Individual t-tests were used to test specific hypotheses about differences between EphB1+/+ and EphB1-/- mice in behavioral responses to morphine withdrawal. Chi-square tests were used to identify differences in the incidence of effects. All data are presented as mean +/- SE. Statistical results are considered significant if p < 0.05.
###end p 55
###begin title 56
Abbreviations
###end title 56
###begin p 57
###xml 30 32 30 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
AP: action potential; CaMK: Ca2+/calmodulin-dependent kinase; CCI: Chronic constriction injury of the sciatic nerve; CREB: cyclic AMP related element binding; DRG: Dorsal root ganglion; DH: spinal dorsal horn; ERK: extracellular signal-regulated kinase; MAPK: mitogen activated protein kinase; MOR: mu-opioid receptor; NMDA: N-methyl-D-aspartate; NO: nitric oxide; RMP: resting membrane potential; RTK: receptor tyrosine kinase.
###end p 57
###begin title 58
Competing interests
###end title 58
###begin p 59
The authors declare that they have no competing interests.
###end p 59
###begin title 60
Authors' contributions
###end title 60
###begin p 61
###xml 239 243 <span type="species:ncbi:10090">mice</span>
XJS planned and participated in conducting the studies and wrote the paper. YH, XSS and WTL conducted the behavioral and/or electrophysiological studies and data analysis. MH generated and identified the EphB1 receptor protein-null mutant mice and kept stimulating discussion on the project with XJS. All the authors approved the final manuscript.
###end p 61
###begin title 62
Acknowledgements
###end title 62
###begin p 63
###xml 213 217 <span type="species:ncbi:10090">mice</span>
We thank Z.-J. Huang and J.-L. Cao for participating in part of the preliminary data collection and/or data analysis, M. Chumley for assistance in generating and identifying the EphB1 receptor protein-null mutant mice, R.L. Rupert and Maria Dominguez for their advice and assistance in management among laboratories. This work was supported by grants from Parker Research Foundation (PCCRF-BSR0703/0804), National Institutes of Health (R01 EY017434 and 2R01 MH66332) and National Natural Science Foundation of China (NSFC-30628027). There are no conflicts of interest.
###end p 63
###begin article-title 64
The Pathology of Damaged Peripheral Nerves
###end article-title 64
###begin article-title 65
Synaptic reorganization in the substantia gelatinosa after peripheral nerve neuroma formation: aberrant innervation of lamina II neurons by Abeta afferents
###end article-title 65
###begin article-title 66
Pathobiology of neuropathic pain
###end article-title 66
###begin article-title 67
Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord
###end article-title 67
###begin article-title 68
Hyperalgesia and neural excitability following injuries to central and peripheral branches of axons and somata of dorsal root ganglion neurons
###end article-title 68
###begin article-title 69
Somata of nerve-injured sensory neurons exhibit enhanced responses to inflammatory mediators
###end article-title 69
###begin article-title 70
Role of the immune system in chronic pain
###end article-title 70
###begin article-title 71
Cellular signalling pathways of spinal pain neuroplasticity as targets for analgesic development
###end article-title 71
###begin article-title 72
EphrinB activation of EphB receptors is critical for production and persistence of hyperalgesia and hyperexcitability of spinal dorsal horn neurons after peripheral nerve injury
###end article-title 72
###begin article-title 73
The development and modulation of nociceptive circuitry
###end article-title 73
###begin article-title 74
###xml 81 85 <span type="species:ncbi:10116">rats</span>
cAMP and cGMP contribute to sensory neuron hyperexcitability and hyperalgesia in rats with dorsal root ganglia compression
###end article-title 74
###begin article-title 75
Central sensitization: uncovering the relation between pain and plasticity
###end article-title 75
###begin article-title 76
Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801
###end article-title 76
###begin article-title 77
Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor
###end article-title 77
###begin article-title 78
Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions
###end article-title 78
###begin article-title 79
Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence
###end article-title 79
###begin article-title 80
Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs
###end article-title 80
###begin article-title 81
Clinical pharmacology of opioids for pain
###end article-title 81
###begin article-title 82
###xml 63 67 <span type="species:ncbi:10090">mice</span>
Locus-specific rescue of GluRepsilon1 NMDA receptors in mutant mice identifies the brain regions important for morphine tolerance and dependence
###end article-title 82
###begin article-title 83
Essential role for RGS9 in opiate action
###end article-title 83
###begin article-title 84
Opioids: cellular mechanisms of tolerance and physical dependence
###end article-title 84
###begin article-title 85
###xml 116 120 <span type="species:ncbi:10090">mice</span>
Therapeutic manipulation of peroxynitrite attenuates the development of opiate-induced antinociceptive tolerance in mice
###end article-title 85
###begin article-title 86
When it comes to opiates, just say NO
###end article-title 86
###begin article-title 87
Dissociation of dorsal root ganglion neurons induces hyperexcitability that is maintained by increased responsiveness to cAMP and cGMP
###end article-title 87
###begin article-title 88
cGMP produced by NO-sensitive guanylyl cyclase essentially contributes to inflammatory and neuropathic pain by using targets different from cGMP-dependent protein kinase I
###end article-title 88
###begin article-title 89
###xml 27 32 <span type="species:ncbi:10090">mouse</span>
EphB receptor signaling in mouse spinal cord contributes to physical dependence on morphine
###end article-title 89
###begin article-title 90
Upregulation and redistribution of ephrinB and EphB receptor in dorsal root ganglion and spinal dorsal horn neurons after peripheral nerve injury and dorsal rhizotomy
###end article-title 90
###begin article-title 91
###xml 122 126 <span type="species:ncbi:10116">rats</span>
Ephrin-EphB receptor signaling contributes to neuropathic pain by regulating neural excitability and spinal plasticity in rats
###end article-title 91
###begin article-title 92
Interactions of Eph-related receptors and ligands confer rostrocaudal pattern to trunk neural crest migration
###end article-title 92
###begin article-title 93
Eph family transmembrane ligands can mediate repulsive guidance of trunk neural crest migration and motor axon outgrowth
###end article-title 93
###begin article-title 94
Eph receptors and ephrins: regulators of guidance and assembly
###end article-title 94
###begin article-title 95
Multiple roles of EPH receptors and ephrins in neural development
###end article-title 95
###begin article-title 96
EphB receptors interact with NMDA receptors and regulate excitatory synapse formation
###end article-title 96
###begin article-title 97
Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors
###end article-title 97
###begin article-title 98
Hippocampal plasticity requires postsynaptic ephrinBs
###end article-title 98
###begin article-title 99
Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions
###end article-title 99
###begin article-title 100
###xml 76 79 <span type="species:ncbi:10116">rat</span>
Inhibition of morphine withdrawal by the NMDA receptor antagonist MK-801 in rat is age-dependent
###end article-title 100
###begin article-title 101
Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity
###end article-title 101
###begin article-title 102
Opiate physical dependence and N-methyl-D-aspartate receptors
###end article-title 102
###begin article-title 103
###xml 155 159 <span type="species:ncbi:10116">rats</span>
Inhibition of the amygdala and hippocampal calcium/calmodulin-dependent protein kinase II attenuates the dependence and relapse to morphine differently in rats
###end article-title 103
###begin article-title 104
Molecular mechanisms in dizocilpine-induced attenuation of development of morphine dependence: an association with cortical Ca2+/calmodulin-dependent signal cascade
###end article-title 104
###begin article-title 105
Increased expression of Ca2+/calmodulin-dependent protein kinase II alpha during chronic morphine exposure
###end article-title 105
###begin article-title 106
A neuroactive steroid, dehydroepiandrosterone sulfate, prevents the development of morphine dependence and tolerance via c-fos expression linked to the extracellular signal-regulated protein kinase
###end article-title 106
###begin article-title 107
###xml 89 92 <span type="species:ncbi:10116">rat</span>
IL-1 beta alters the expression of the receptor tyrosine kinase gene r-EphA3 in neonatal rat cardiomyocytes
###end article-title 107
###begin article-title 108
###xml 122 126 <span type="species:ncbi:10116">rats</span>
Ephrin-B2 and EphB2 regulation of astrocyte-meningeal fibroblast interactions in response to spinal cord lesions in adult rats
###end article-title 108
###begin article-title 109
The development of nociceptive circuits
###end article-title 109
###begin article-title 110
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
Involvement of interferon-gamma and its receptor in the activation of astrocytes in the mouse hippocampus following entorhinal deafferentation
###end article-title 110
###begin article-title 111
Roles of Eph receptors and ephrins in the normal and damaged adult CNS
###end article-title 111
###begin article-title 112
Release of full-length EphB2 receptors from hippocampal neurons to cocultured glial cells
###end article-title 112
###begin article-title 113
EphB receptors and ephrin-B ligands regulate spinal sensory connectivity and modulate pain processing
###end article-title 113
###begin article-title 114
Involvement of EphB1 receptor/EphrinB2 ligand in neuropathic pain
###end article-title 114
###begin article-title 115
###xml 116 119 <span type="species:ncbi:9685">cat</span>
Effects of central or peripheral axotomy on membrane properties of sensory neurones in the petrosal ganglion of the cat
###end article-title 115
###begin article-title 116
Electrophysiological characteristics of hamster dorsal root ganglion cells and their response to axotomy
###end article-title 116
###begin article-title 117
###xml 84 88 <span type="species:ncbi:10116">rats</span>
Spontaneous action potential activity in isolated dorsal root ganglion neurons from rats with a painful neuropathy
###end article-title 117
###begin article-title 118
Mechanical and thermal hyperalgesia and ectopic neuronal discharge after chronic compression of dorsal root ganglia
###end article-title 118
###begin article-title 119
Changes in the action potential in sensory neurones after peripheral axotomy in vivo
###end article-title 119
###begin article-title 120
###xml 73 76 <span type="species:ncbi:10116">rat</span>
Axotomy- and autotomy-induced changes in Ca2+ and K+ channel currents of rat dorsal root ganglion neurons
###end article-title 120
###begin article-title 121
Mechanisms and functions of Eph and ephrin signalling
###end article-title 121
###begin article-title 122
Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function
###end article-title 122
###begin article-title 123
EphrinB2 induces tyrosine phosphorylation of NR2B via Src-family kinases during inflammatory hyperalgesia
###end article-title 123
###begin article-title 124
###xml 64 67 <span type="species:ncbi:10116">rat</span>
Inhibition of calcium/calmodulin-dependent protein kinase II in rat hippocampus attenuates morphine tolerance and dependence
###end article-title 124
###begin article-title 125
CREB: a Ca(2+)-regulated transcription factor phosphorylated by calmodulin-dependent kinases
###end article-title 125
###begin article-title 126
ERK activation causes epilepsy by stimulating NMDA receptor activity
###end article-title 126
###begin article-title 127
The cyclic AMP response element in the calcitonin/calcitonin gene-related peptide gene promoter is necessary but not sufficient for its activation by nerve growth factor
###end article-title 127
###begin article-title 128
Chronic morphine exposure increases the phosphorylation of MAP kinases and the transcription factor CREB in dorsal root ganglion neurons: an in vitro and in vivo study
###end article-title 128
###begin article-title 129
Ephrin-B3 is a myelin-based inhibitor of neurite outgrowth
###end article-title 129
###begin article-title 130
Central sensitization and LTP: do pain and memory share similar mechanisms?
###end article-title 130
###begin article-title 131
Manipulation of EphB2 regulatory motifs and SH2 binding sites switches MAPK signaling and biological activity
###end article-title 131
###begin article-title 132
Mitogen-activated protein kinases as potential targets for pain killers
###end article-title 132
###begin article-title 133
A neuronal isoform of protein kinase G couples mitogen-activated protein kinase nuclear import to axotomy-induced long-term hyperexcitability in Aplysia sensory neurons
###end article-title 133
###begin article-title 134
The roles of sodium channels in nociception: Implications for mechanisms of pain
###end article-title 134
###begin article-title 135
The sodium channel Nav1.7 is a substrate and is modulated by the MAP kinase ERK
###end article-title 135
###begin article-title 136
The role of ERK activation in the neuronal excitability in the chronically compressed dorsal root ganglia
###end article-title 136
###begin article-title 137
Multiple EphB receptor tyrosine kinases shape dendritic spines in the hippocampus
###end article-title 137
###begin article-title 138
Ephrin-B2 and EphB1 mediate retinal axon divergence at the optic chiasm
###end article-title 138
###begin article-title 139
###xml 31 34 <span type="species:ncbi:10116">rat</span>
###xml 96 99 <span type="species:ncbi:9606">man</span>
A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man
###end article-title 139

